Biotech IPOs can look like rocket fuel—until patent due diligence turns out to be the handbrake.
If you’re an investor, a founder, or even a board member, the most expensive surprises in life sciences rarely come from the science. They come from the pa…

Most biosimilar models fail for the same reason: they assume the market will behave like a spreadsheet.
That’s the uncomfortable takeaway from a recent DrugPatentWatch piece on the costly mistakes companies make when modeling biosimilar entry windows…

Most teams don’t fail at “strategy.” They fail at “timing.”
In generic and biosimilar development, the difference between a confident go decision and a costly misstep is often not the science—it’s the patent landscape you relied on before you filed.
He…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the first patent you see is rarely the last one you’ll face.
That’s the uncomfortable reality behind “secondary formulation” paten…

Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …

Your pharmaceutical portfolio may be “working”… right up until it isn’t.
Here’s the uncomfortable truth: patent expiration doesn’t arrive like a storm warning. It shows up like a calendar invite—quietly, precisely, and with consequences that ripple thr…

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…

Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…

Dairy-Free Alternatives to Lipitor: Exploring Options for Statin-Free Heart Health As the world becomes increasingly aware… https://www.Drugchatter.com/chat/1561/are-there-any-dairy-free-alternatives-to-lipitor/